IceCure Medical (NASDAQ:ICCM) Given “Buy” Rating at HC Wainwright

IceCure Medical (NASDAQ:ICCM)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research report issued on Wednesday,Benzinga reports. They presently have a $2.50 price target on the stock. HC Wainwright’s price objective would indicate a potential upside of 200.41% from the company’s previous close.

Separately, Alliance Global Partners upgraded shares of IceCure Medical to a “strong-buy” rating in a report on Friday, November 1st.

IceCure Medical Trading Up 5.8 %

Shares of ICCM stock opened at $0.83 on Wednesday. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.97 and a quick ratio of 2.54. The business has a 50-day moving average of $0.65 and a 200 day moving average of $0.73. The stock has a market capitalization of $37.96 million, a PE ratio of -2.77 and a beta of 0.48. IceCure Medical has a 1-year low of $0.48 and a 1-year high of $1.57.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in IceCure Medical stock. Renaissance Technologies LLC bought a new position in IceCure Medical Ltd (NASDAQ:ICCM) in the 2nd quarter, according to its most recent disclosure with the SEC. The firm bought 66,400 shares of the company’s stock, valued at approximately $49,000. Renaissance Technologies LLC owned 0.15% of IceCure Medical at the end of the most recent quarter. 0.62% of the stock is owned by hedge funds and other institutional investors.

IceCure Medical Company Profile

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.